Table 4 Promoter methylation in NSCLC-univariate associations with clinicopathologic characteristics (OR^† and 95% CI)

CALCA

0.73 (0.28-1.90)

0.94 (0.58-1.52)

1.43 (0.57-3.57)

0.88 (0.51-1.51)

2.21 (0.89-5.47)

CDH1

2.13 (0.86-5.22)

0.83 (0.53-1.30)

1.41 (0.59-3.39)

0.91 (0.55-1.50)

2.63 (1.05-6.60)*

DAPK1

1.45 (0.43-4.87)

1.16 (0.60-2.24)

2.11 (0.64-6.92)

1.83 (0.84-3.98)

6.64 (1.85-23.8)*

IRX2

1.29 (0.54-3.06)

0.76 (0.48-1.19)

1.06 (0.45-2.52)

0.91 (0.55-1.50)

2.89 (1.17-7.13)*

TIMP3

1.09 (0.46-2.60)

1.09 (0.70-1.71)

1.09 (0.46-2.60)

1.27 (0.76-2.11)

2.51 (1.01-6.21)*

PAX6

1.04 (0.37-2.88)

1.19 (0.70-2.03)

0.78 (0.27-2.25)

0.93 (0.51-1.69)

1.04 (0.37-2.88)

Genes

Tumor size ²

Lymph node metastasis

Pleural indentation

Invasion or Adhesion

Histologic stage ³

CALCA

1.01 (0.55-1.88)

1.74 (0.62-4.91)

1.18 (0.41-3.41)

2.44 (0.88-6.79)

2.13 (1.01-4.47)*

CDH1

1.20 (0.67-2.13)

1.02 (0.41-2.51)

1.79 (0.67-4.76)

0.96 (0.41-2.27)

1.11 (0.62-2.02)

DAPK1

1.81 (0.72-4.54)

5.17 (0.64-41.95)

1.63 (0.33-8.02)

1.70 (0.43-6.67)

1.24 (0.50-3.08)

IRX2

1.57 (0.88-2.83)

1.17 (0.47-2.88)

1.37 (0.52-3.63)

0.86 (0.36-2.01)

1.14 (0.63-2.07)

TIMP3

1.67 (0.92-3.01)

2.05 (0.82-5.10)

1.16 (0.44-3.05)

0.69 (0.29-1.66)

1.88 (1.01-3.49)*

PAX6

0.78 (0.40-1.54)

0.74 (0.26-2.09)

2.04 (0.54-7.69)

1.84 (0.61-5.56)

1.76 (0.79-3.93)